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  23 
ABSTRACT 24 
Background – Adrenaline is the primary drug of choice for resuscitation from out-of-hospital cardiac 25 
arrest (OHCA). Although adrenaline may increase the chance of achieving return of spontaneous 26 
circulation (ROSC), there is limited evidence that repeated doses of adrenaline improves overall 27 
survival, and increasing evidence of a detrimental effect on neurological function in survivors. This 28 
paper reports the relationship between repeated doses of adrenaline and survival in a cohort of patients 29 
attended by the London Ambulance Service in the United Kingdom. 30 
Methods – A retrospective review of OHCA treated by the London Ambulance Service over a one 31 
year period. Patients aged ≥18 years who received one or more doses of adrenaline (1 mg bolus) 32 
during resuscitation were included in the analyses. Outcomes described are survival to hospital 33 
discharge and survival to one year post-arrest. 34 
Results – Over the one year study period, 3,151 patients received adrenaline during OHCA. A 35 
significant inverse relationship was found between increasing cumulative doses of adrenaline and 36 
survival both to hospital discharge and one year post-arrest. No patients survived after receiving more 37 
than ten adrenaline doses. 38 
Conclusion – Our study indicates that repeated doses of adrenaline are associated with decreasing 39 
odds of survival. There were no survivors amongst patients requiring more than 10 doses of 40 
adrenaline. 41 
   42 
 43 
  44 
INTRODUCTION 45 
The administration of adrenaline has been the cornerstone of treatment for out-of-hospital cardiac 46 
arrest (OHCA) for decades1. Resuscitation guidelines worldwide recommend the use of adrenaline, 47 
administered every 3-5 minutes, as part of advanced life support for cardiac arrest from all causes and 48 
all rhythms2-5. 49 
Evidence for a short-term beneficial effect of adrenaline in achieving return of spontaneous 50 
circulation (ROSC) after an OHCA has been reported in several observational studies and meta-51 
analyses6-11. Notably, the recent randomised, double-blind PARAMEDIC2 trial, conducted within 52 
ambulance services in the United Kingdom (UK), found a higher rate of ROSC, with a small increase 53 
in survival to hospital discharge (<1%)12, something supported by two previous randomised studies13, 54 
14.  55 
Irrespective of any effect on survival, concern about the use of adrenaline in OHCA has been 56 
growing, with accumulating evidence indicating that its use may be harmful, particularly in terms of 57 
poorer neurological functioning7, 9, 15-17.  58 
There are also questions around the quantities and numbers of doses of adrenaline given. One French 59 
study reported no difference in survival between repeated administrations of high-dose (5mg) 60 
adrenaline and standard-dose (1mg) adrenaline18, while reporting a slight increase in ROSC in the 61 
high-dose group. Another study from America reported higher rates of survival with less frequent 62 
administration of adrenaline than the recommended 3-5 minutes frequency of administration, 63 
indirectly suggesting that larger amounts of adrenaline may have poorer outcome. 64 
Our study sought to examine the relationship between repeated (1mg) doses of adrenaline and 65 
survival, and explore whether there is a point during OHCA after which the administration of further 66 
doses, as currently recommended, becomes futile. 67 
  68 
METHODS 69 
Study design 70 
A retrospective, observational analysis using anonymised data from the London Ambulance Service 71 
(LAS) cardiac arrest registry over a one-year period (1st April 2012–31st March 2013). Ethical 72 
approval was not required as this study used data routinely collected for clinical audit purposes. 73 
Patient population 74 
All adult patients (≥18 years of age) who experienced an OHCA of presumed cardiac aetiology, and 75 
received one or more doses of adrenaline (1 mg bolus) during resuscitation, were eligible for inclusion 76 
in this study.  77 
Study setting 78 
The LAS covers the geographical area of Greater London, UK, which spans approximately 620 79 
square miles and serves a population of 8.4 million people19. During the study period, more than 1 80 
million incidents were attended by the LAS20, with over 10,000 of these being OHCA21.  81 
Calls identified as ‘cardiac arrest’ (using the advanced Medical Priority Dispatch System) receive the 82 
highest level response, with a minimum of two emergency vehicles, staffed by at least one paramedic 83 
(trained in advanced life support), being dispatched to the incident.  84 
All LAS clinicians operate to the Resuscitation Council (UK) guidelines2, which advise the 85 
administration of adrenaline (intravenous or intraosseous) for all initial rhythms during an OHCA. If 86 
the patient presents in ventricular fibrillation or pulseless ventricular tachycardia (VF/pVT), a 1 mg 87 
bolus of adrenaline is administered after 3 unsuccessful defibrillation attempts, whereas for non-88 
shockable rhythms (pulseless electrical activity (PEA) or asystole) a 1 mg bolus of adrenaline is 89 
administered as soon as possible. If the cardiac arrest persists, a further dose of adrenaline is advised 90 
every 3-5 minutes with no upper dose limit until either ROSC is achieved and the patient is handed 91 
over to hospital, or the resuscitation attempt is terminated. If ROSC is achieved, local LAS protocol 92 
allows a lower dose of adrenaline (0.1 mg bolus) to be administered to maintain the patient’s blood 93 
pressure and prevent re-arrest.  94 
Data collection  95 
Data were obtained from the LAS Out-of-Hospital Cardiac Arrest Registry that collates patient, 96 
process, treatment and outcome information from multiple sources (including emergency dispatch call 97 
logs, and ambulance service and hospital clinical patient records) to provide a comprehensive clinical 98 
record for each OHCA. Characteristics and outcomes recorded include: patient demographics, 99 
location of arrest, presenting cardiac rhythm, bystander intervention, pre-hospital resuscitation 100 
methods, ROSC and survival to hospital discharge. Long-term outcome, with survival up to 1 year 101 
post-arrest, was obtained from NHS Digital Summary Care Records.   102 
Data analysis 103 
Data analysis and statistics were performed using Excel (Microsoft, Redmond, WA), SPSS v23 (IBM, 104 
Armonk, NY) and R 3.5.1 (A Language and Environment for Statistical Computing). Statistical 105 
significance was accepted when p<0.05. 106 
The association between percentage survival (to hospital discharge and to one year post-arrest) and 107 
independent explanatory variables was assessed using a step-wise multivariate logistic regression 108 
model. We first undertook univariate logistic regressions on all known predictors of survival (age, 109 
sex, adrenaline dose group, initial shockable rhythm, time from EMS call to first adrenaline dose, 110 
ROSC, bystander CPR, and witness status). We then built a step-wise multivariate regression model 111 
starting with the predictor that had the strongest association with the outcome based on the partial F-112 
tests obtained from the regression. At each step we added the predictor that had the next strongest 113 
association or excluded the predictor that no longer explained the outcome. We stopped this procedure 114 
when no more predictors could be added or removed, and this is the final model upon which the 115 
results are based. Collinearity between the predictors was assessed by calculating the variance 116 
inflation factor (VIF) for each predictor and excluding those variables that had a VIF greater than 5. 117 
No predictor met this criterion and therefore none were removed from analysis based on collinearity. 118 
The number of doses of adrenaline were categorised into three categories, 1 dose, 2 doses, and >3 119 
doses in the multivariate analysis.  120 
When presenting results, continuous variables are presented as means ± standard deviation (SD) and 121 
categorical variables are reported as counts with relative frequencies. Adjusted odds ratios (AOR) and 122 
95% confidence intervals (CI) obtained from the multi-variable binomial logistic regression after 123 
controlling for potential confounders were used to interpret associations between variables and 124 
outcomes.  125 
  126 
RESULTS 127 
Resuscitation was attempted for 4,466 OHCA patients; with 3,151 (71%) meeting the criteria for 128 
inclusion in the study (see Figure 1). In total, 137 (4.3%) patients survived to be discharged from 129 
hospital, with 108 of 122 patients (88.5%; with 15 lost to follow up) still alive at one year 130 
(representing 3.4% overall). Patient demographics and key event characteristics based on patient 131 
outcome are summarised in Table 1. Compared to non-survivors, those who survived to one year had 132 
almost four fewer doses of adrenaline on average (p<0.001), presented with an initial shockable 133 
rhythm (VF/VT) (p<0.0001), were more likely to have had a witnessed arrest (p<0.001), received a 134 
higher number of shocks (p<0.001) and had an ‘EMS call’ to ‘administration of first adrenaline dose’ 135 
interval that averaged five minutes faster (p<0.001).  136 
Each one minute of delay from ‘EMS’ call to ‘administration of first adrenaline dose’ was associated 137 
with a 7% reduction in survival (OR = 0.93; CI = 0.91, 0.96; p<0.0001) to both hospital discharge and 138 
one year post arrest. However, this association was no longer significant after adjusting for other 139 
covariates in the multivariate regression model (AOR = 0.98; CI = 0.95, 1.00; p=0.09).  140 
Association of repeated doses of adrenaline and survival 141 
The relationship between repeated adrenaline doses and survival both to hospital discharge and to one 142 
year post-arrest is presented in Figure 2 and Supplementary Table 1. The number of adrenaline doses 143 
administered had a negative association with both measures of survival. Survival to hospital discharge 144 
was approximately 20% with one dose of adrenaline, rapidly declining to less than 2% at five or more 145 
doses. Survival to one year followed a similar pattern. There were no survivors amongst patients who 146 
received more than 10 doses of adrenaline.   147 
While  there were variables listed in Table 1 that were significantly associated with survival at the 148 
univariate level, only adrenaline dose group, presence of an initial shockable rhythm, age and sex 149 
could significantly predict survival in the step-wise regression model. Therefore we present 150 
association of adrenaline dose group with survival after adjusting for the significant confounders, 151 
initial shockable rhythm, age and sex.  152 
Multivariate analysis revealed that when adjusted for the effects of age, sex, and an initial shockable 153 
rhythm, three or more doses of adrenaline were associated with an 85% decrease in the likelihood of 154 
surviving to hospital discharge (AOR = 0.15; CI = 0.09, 0.26; p<0.0001) and an 82% decrease in 155 
surviving to one year (AOR = 0.18; CI =0.1, 0.11; p<0.0001). Full analysis results are detailed in 156 
Table 2. 157 
Two patients (out of 190; 1.1%) who received 9 doses of adrenaline, and a further 2 patients (out of 158 
224; 0.9%) who received exactly 10 doses of adrenaline, survived to hospital discharge and were still 159 
alive at one year (see Supplementary Table 2 for details of these patients). The first dose of adrenaline 160 
was administered to all four patients in less than 13 minutes from initiation of CPR, well within the 161 
overall average (15 minutes). All cases had an end-tidal carbon dioxide (ETCO2) value over 20 162 
mmHg with Cases 1 and 3 exceeding 30 mmHg. Case 2, 3 and 4 had intermittent ROSC during 163 
resuscitation, with Cases 1, 2 and 3 achieving a stable ROSC which was sustained from the arrest 164 
location to hospital handover. In addition, the three patients who suffered a myocardial infarction 165 
(Cases 1, 2 and 4) were conveyed by ambulance directly to a specialist heart attack centre for 166 
coronary intervention. 167 
A total of 267 patients received more than 10 doses of adrenaline, and none survived. Using the ‘rule 168 
of three’22 our study predicts that more than 10 doses of adrenaline will result in no more than 1.1% 169 
(95% CI 0-1.1) of patients surviving to hospital discharge and one year post arrest.  170 
 171 
  172 
DISCUSSION 173 
This study sought to describe the association between repeated doses of adrenaline and survival. We 174 
found that three or more doses were associated with a significant reduction in the odds of surviving to 175 
both hospital discharge and to one year post-arrest. The decline in survival was evident up to five 176 
cumulative doses of adrenaline, at which point the relationship flattened due to very few survivors, 177 
with no survivors after ten doses. The significant inverse relationship between cumulative doses of 178 
adrenaline and survival persisted even after adjusting for potential confounders using multivariate 179 
analysis.  180 
These results support the findings of Glover et al23 who described an independent negative association 181 
between the probability of survival to hospital discharge and adrenaline dose in the US and Canada. 182 
We found four patients who, despite a higher number of adrenaline doses (9 or 10 doses), were still 183 
alive one year post-arrest. However, it is likely that the favourable factors observed (which included a 184 
reversible cause of arrest, conveyance to a specialist centre, and a short time to first adrenaline dose) 185 
contributed to their survival. 186 
While in our study, ‘EMS call’ to ‘administration of first adrenaline dose’ interval was not 187 
significantly associated with survival after adjusting for confounders, previous studies have identified 188 
a relationship between time to first dose of adrenaline and survival  24-28 in their multivariate models. 189 
Hubble et al observed a 4% reduction in the odds of obtaining ROSC for every one minute delay from 190 
emergency call to administration of a vasopressor24. Two other studies suggested that, when 191 
administered within 20 minutes of the emergency call, repeated doses of adrenaline were associated 192 
with improved neurological outcome for witnessed cardiogenic OHCA25, 26.  Hayashi et al further 193 
demonstrated that for patients in VF/VT27, administration of adrenaline within 10 minutes of the 194 
emergency call was associated with better one-month neurological outcome28. In our study, those who 195 
survived to one year had an ‘EMS call’ to ‘first adrenaline dose’ time interval that was, on average, 196 
five minutes faster compared to those who died.  It is to be noted however, that variables used to build 197 
multivariate models differed in all these studies and perhaps could explain the difference in results. 198 
Being an observational study, we were unable to separate the effect of the number of adrenaline 199 
doses, from the length of time a patient was in cardiac arrest and the severity of their condition, both 200 
of which are known to influence outcome29.  As such, our findings must be interpreted with caution. It 201 
is likely that cumulative doses of adrenaline are a proxy for cardiac arrest duration, which is 202 
associated with increasingly poor outcome, a phenomenon that has been termed ‘resuscitation time 203 
bias’29. However, given that adrenaline increases the likelihood of achieving ROSC, these two 204 
variables are heavily interdependent. The observed effects may also be attributed to other unknown 205 
confounders. 206 
There are further limitations in the data available for our study. We were unable to obtain neurological 207 
outcomes from hospitals, and this would have provided a valuable insight into the neurological effects 208 
of cumulative adrenaline doses and the quality of life for OHCA survivors. Technological limitations 209 
within our EMS system prevented defibrillator downloads from being available for analysis; these 210 
data would have enabled us to assess the quality of CPR, something which may have impacted on 211 
drug delivery and subsequent efficacy30.  212 
Despite the limitations, our findings support the need for further research into the efficacy, timing and 213 
dosage of adrenaline during resuscitation. Current guidelines recommend administration of adrenaline 214 
(1 mg) every 3-5 minutes2; however, in-hospital studies suggest that a less frequent dosing strategy 215 
may increase survival31 and could reduce development of secondary VF/VT32.  One study comparing 216 
high-dose adrenaline (15mg) with the standard dose (1 mg), documented an increase in ROSC and 217 
survival to hospital admission with the higher dose33. In contrast, Frisk et al investigated a lower 218 
adrenaline dose (0.5 mg), which did not affect survival to hospital discharge or favourable 219 
neurological outcome for OHCA patients34. It is clear that the optimum dose of adrenaline is a 220 
knowledge gap that needs further investigation35.  221 
 222 
Conclusion 223 
Our study indicates that repeated doses of adrenaline are associated with decreasing odds of 224 
survival.  There were no survivors amongst patients requiring more than 10 doses of adrenaline. 225 
 226 
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FIGURE LEGENDS 233 
Figure 1. Overview of cases meeting our inclusion criteria and outcomes. 234 
Figure 2. Relationship between the number of adrenaline doses and percentage survival to hospital 235 
discharge  and survival to 1-year post-arrest. Shaded regions represent 95% confidence interval. 33 236 
unknown outcomes were excluded from analysis.  237 
TABLE LEGENDS 238 
Table 1. Patient demographics and key event characteristics for out-of-hospital cardiac arrests 239 
(OHCA) where one or more dose of adrenaline (1 mg) was administered during resuscitation. 240 
Univariate analysis was used to compare patients who survived to 1 year and those who died. 33 cases 241 
were excluded from analysis due to unknown outcomes. SD, standard deviation; CPR, 242 
cardiopulmonary resuscitation; EMS, emergency medical service; VF, ventricular fibrillation; pVT, 243 
pulseless ventricular tachycardia; PEA, pulseless electrical activity. 244 
Table 2. Adjusted odds ratios (AOR) for survival to hospital discharge and 1 year post-arrest. 245 
Multivariate analysis was used to control for potential confounders listed on Table 1. †An adjusted 246 
odds ratio above 1.0 favors survival. SD, standard deviation; CI, confidence interval. 247 
 248 
SUPPLEMENTARY FIGURES 249 
Supplementary Table 1. Cardiac arrest cases attended from 2012-2013 by the London Ambulance 250 
Service: doses of adrenaline and return of spontaneous circulation (ROSC) sustained to hospital, 251 
outcome hospital discharge and 1 year post-arrest for all initial rhythms. All percentages were 252 
calculated as a percentage of total counts for each adrenaline dose.  253 
Supplementary Table 2. Case review of patients who received 9 or 10 doses of adrenaline for an out-254 
of-hospital cardiac arrest and survived. M, male; CPR, cardiopulmonary resuscitation; VF, ventricular 255 
fibrillation; VT, ventricular tachycardia; PEA, pulseless electrical activity; EMS, emergency medical 256 
service; ROSC, return of spontaneous circulation.  257 
Supplementary Table 3. Cardiac arrest cases attended from 2012-2013 by the London Ambulance 258 
Service: doses of adrenaline and outcome at 1 year post-arrest are broken down by initial rhythms. All 259 
percentages were calculated as a percentage of total counts for each adrenaline dose.   260 
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